Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine as adjuvant in peribulbar cataract surgery
NCT03436836Completed
- Sponsor
- Cairo University
- Start
- Jan 2018
- Primary completion
- Feb 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of nalbuphine in cataract, sponsored by Cairo University. Primary endpoint: Duration of sensory block at 12 hours. Started Jan 2018; status: completed.
02
Drugs
nalbuphine
03
Conditions
cataract
Beyond the preview
Go deeper on NCT03436836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436836.